News Results
There are 370,261 News Results
Nov 4, 2024
-- Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from...
Nov 4, 2024
Third quarter Goodyear net loss of $34 million (12 cents per share); adjusted net income of $105 million (37 cents per share) Segment operating income of $347 million; SOI margin...
Nov 5, 2024
- New revumenib and Niktimvo(TM) clinical data will be highlighted at 66(th) ASH Annual Meeting -
Nov 6, 2024
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs...
Nov 7, 2024
- 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy -
Nov 7, 2024
-- Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 -- Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under...
Nov 7, 2024
MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended September 27,...
Nov 7, 2024
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter...
Nov 7, 2024
ORLANDO, Fla., Nov. 7, 2024 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ: LPTH) ("LightPath," the "Company," or "we"), a leading provider of next-generation optics and imaging systems for both defense and...
Nov 11, 2024
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance
